Role of Second-Line Systemic Treatment Post-Docetaxel in Metastatic Castrate Resistant Prostate Cancer- Current Strategies and Future Directions

Author(s): Jawaher Ansari, Syed A Hussain, Abdulla Alhasso, Rana Mahmood, Asif Ansari, John Glaholm

Journal Name: Anti-Cancer Agents in Medicinal Chemistry
(Formerly Current Medicinal Chemistry - Anti-Cancer Agents)

Volume 11 , Issue 3 , 2011

Become EABM
Become Reviewer
Call for Editor


Treatment of metastatic castrate resistant prostate cancer (mCRPC) after progression on docetaxel chemotherapy is a challenging clinical scenario with limited availability of treatment options. Re-treatment with docetaxel, either as monotherapy or in combination with other cytotoxics or targeted agents has shown durable responses. However, most docetaxel re-treatment studies have been either retrospective or early phase non-randomised studies which have not formally assessed Quality of life or survival gain with re-treatment. Despite limited evidence for efficacy of mitoxantrone in the second-line, it continues to remain widely used, largely due to lack of available suitable alternatives. Cabazitaxel in combination with prednisolone is the only chemotherapy to have shown a significant survival benefit and receive approval by the U.S. Food and Drug Administration for patients with mCRPC previously treated with a docetaxel-based regimen. Abiraterone acetate has recently demonstrated a significant improvement in survival when compared to placebo in patients with docetaxel-treated mCRPC. This review aims to summarize the current evidence and discuss future strategies for treatment of mCRPC patients following failure of docetaxel chemotherapy.

Keywords: Metastatic castrate resistant prostate cancer, post-docetaxel chemotherapy, metastatic prostate cancer, docetaxel resistant prostate cancer, abiraterone, cabazitaxel, Prostate Cancer, mCRPC, Docetaxel, Bevacizumab, Carboplatin, Estramustine, MITOXANTRONE CHEMOTHERAPY, Platinum-Based Chemotherapy

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2011
Published on: 01 March, 2012
Page: [296 - 306]
Pages: 11
DOI: 10.2174/187152011795347496
Price: $65

Article Metrics

PDF: 16